Article metrics
PDF
Other content recommended for you
- Research ethics and evidence based medicine
- The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
- NICE is dead; long live NICE
- NICE’s new methods: putting innovation first, but at what cost?
- NICE: faster access to modern treatments? Analysis of guidance on health technologies
- The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis
- The unintended consequences of NICE
- Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator
- National Institute for Clinical Excellence and its value judgments
- Wickedness or folly? The ethics of NICE’s decisions